Physician profile
Yaron Bareket
NPI 1376548719
$17,386.71
in general payments reported to CMS, 2019-2025
21 companies · $560 in 2025
The $560 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $2,426 · 2021: $1,066 · 2022: $709 · 2023: $1,100 · 2024: $626 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,285.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $14,353.64 | 2019-2024 | Xarelto |
| Medtronic, INC. | $712.07 | 2021-2025 | Micra, Aurora Ev-Icd Mri Surescan |
| Amgen INC. | $432.26 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $339.44 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $325.61 | 2021-2025 | Verquvo |
| Abbott Laboratories | $294.37 | 2022-2024 | Mitraclip |
| E.R. Squibb & Sons, L.L.C. | $205.90 | 2022-2025 | Camzyos, Eliquis |
| Heartflow, INC. | $163.24 | 2022-2025 | Ffrct |
| Astrazeneca Pharmaceuticals LP | $143.33 | 2024 | Wainua, Farxiga |
| Pfizer INC. | $71.31 | 2021-2024 | |
| Amarin Pharma, INC. | $67.66 | 2021 | |
| Bridgebio Pharma, INC. | $64.03 | 2025 | Attruby |
| Atricure, INC. | $63.13 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $31.51 | 2023-2024 | Inpefa |
| Boston Scientific Corporation | $29.10 | 2020-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $18.15 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $17.16 | 2024 | Opsumit |
| Kiniksa Pharmaceuticals, LTD. | $14.29 | 2023 | Arcalyst |
| Scpharmaceuticals INC. | $13.86 | 2025 | |
| Sanofi-Aventis U.S. LLC | $13.34 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yaron Bareket listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.